Suppr
超能文献

Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction.

作者信息

Messerli Franz H, Bangalore Sripal

机构信息

From Department of Cardiology and Clinical Research, University Hospital, Bern, Switzerland (F.H.M.); Jagiellonian University, Krakow, Poland (F.H.M.); Division of Cardiology, Mount Sinai Health Medical Center, Icahn School of Medicine, New York, NY (F.H.M.); and Leon H. Charney Division of Cardiology, New York University School of Medicine (S.B.).

出版信息

Circulation. 2017 May 30;135(22):2085-2087. doi: 10.1161/CIRCULATIONAHA.116.025950.

DOI:10.1161/CIRCULATIONAHA.116.025950

PMID:28559492

Abstract

摘要

相似文献

Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction.

Circulation. 2017 May 30;135(22):2085-2087. doi: 10.1161/CIRCULATIONAHA.116.025950.

Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox.

Circulation. 2017 May 30;135(22):2088-2090. doi: 10.1161/CIRCULATIONAHA.117.026112.

Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.

J Hypertens. 2008 Jul;26(7):1282-9. doi: 10.1097/HJH.0b013e328306ebe2.

Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.

Eur J Prev Cardiol. 2017 Dec;24(18):1914-1924. doi: 10.1177/2047487317728766. Epub 2017 Sep 1.

Incidence of new stroke or new myocardial infarction or death at 39-month follow up in patients with diabetes mellitus, hypertension, or both treated with and without angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Am J Ther. 2009 Jan-Feb;16(1):2-4. doi: 10.1097/MJT.0b013e31804d1b53.

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.

Eur Heart J. 2012 Feb;33(4):505-14. doi: 10.1093/eurheartj/ehr400. Epub 2011 Oct 31.

Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.

PLoS One. 2017 Dec 7;12(12):e0188720. doi: 10.1371/journal.pone.0188720. eCollection 2017.

Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.

Am J Cardiovasc Drugs. 2015 Dec;15(6):439-49. doi: 10.1007/s40256-015-0140-5.

[The effect of ARB on prevention of atherosclerosis].

Nihon Rinsho. 2011 Jan;69(1):92-9.

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk.

Am J Cardiovasc Drugs. 2016 Dec;16(6):399-406. doi: 10.1007/s40256-016-0185-0.

引用本文的文献

Impact of antihypertensive drug classes on cardiovascular outcomes: insights from the STEP study.

BMC Med. 2025 Jul 1;23(1):365. doi: 10.1186/s12916-025-04158-z.

Comparison of Adverse Events Among Angiotensin Receptor Blockers in Hypertension Using the United States Food and Drug Administration Adverse Event Reporting System.

Cureus. 2025 Apr 8;17(4):e81912. doi: 10.7759/cureus.81912. eCollection 2025 Apr.

Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study.

Pharmaceuticals (Basel). 2023 Sep 14;16(9):1298. doi: 10.3390/ph16091298.

Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction.

PLoS One. 2023 Mar 9;18(3):e0281460. doi: 10.1371/journal.pone.0281460. eCollection 2023.

Association between renin-angiotensin-aldosterone system blockade and clinical outcomes in patients with hypertension: real-world observation from a nationwide hypertension cohort.

Clin Res Cardiol. 2023 Nov;112(11):1577-1586. doi: 10.1007/s00392-023-02179-3. Epub 2023 Mar 3.

The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in elderly (≥ 65) patients with acute myocardial infarction without hypertension.

Heart Vessels. 2023 Jul;38(7):898-908. doi: 10.1007/s00380-023-02244-x. Epub 2023 Feb 16.

Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) Landscape.

Biomedicines. 2021 Aug 11;9(8):997. doi: 10.3390/biomedicines9080997.

Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan.

Biomedicines. 2021 Jul 22;9(8):860. doi: 10.3390/biomedicines9080860.

Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study.

Sci Rep. 2021 Feb 17;11(1):4008. doi: 10.1038/s41598-021-83494-5.

The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension.

PLoS One. 2020 Nov 30;15(11):e0242314. doi: 10.1371/journal.pone.0242314. eCollection 2020.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译